Relapsed/Refractory Follicular Lymphoma Study

Phase: 1b/#

Status: Ongoing

About

A Phase 1b/3 Study in Subjects With Relapsed/Refractory Follicular Lymphoma


Details

Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Sponsor: Epizyme, Inc

NCT04224493

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top